LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT

6 7 月, 2025

One Min Read

10 Views

原文: https://finance.yahoo.com/news/lifesci-capital-maintains-buy-immunovant-081522274.html

Last Update: 6 7 月, 2025

Written By

Other Articles

Previous

POSCO Holdings to Build US Lithium Plant, Supports EV Supply Chain

Next

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

Related Posts

Powerball jackpot soars to $1.3 billion. Here’s what the winner will take home after taxes.

1 Min Read

What is force-placed car insurance, and when do lenders require it?

1 Min Read

Do you need collateral for a personal loan? See when it might help.

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept